DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...
Driving Technology Transfer and Test Manufacturing Following Regulatory Approval to Launch Company-Led af-001 Trial〜 TOKYO, ...
InvestorsHub on MSN
AlphaTON shares surge 200% after unveiling digital asset-powered oncology initiative
Shares of AlphaTON Capital Corp (NASDAQ:ATON) soared 200% on Wednesday after the company announced plans to explore the ...
AlphaTON Capital (ATON), alongside its wholly owned oncology subsidiary Tarus Therapeutics dba Cyncado Therapeutics, announced a non-binding letter of intent to evaluate tokenization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback